https://www.selleckchem.com/pr....oducts/nazartinib-eg
Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012-202 related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies.By submitting this manuscript, each author certifies that they
Like
Comment
Share
